Gene therapy and gene editing technologies encompass a wide range of products, including plasmid DNA, viral vectors, CRISPR, ZFNs, TALENs, and siRNAs. These products have been of significant research interest, especially with the recent approval of breakthrough therapies like Luxturna. However, several hurdles persist for companies seeking to develop these novel therapies.
This application note provides:
- An outline of the complexities present in gene therapy research and development
- How Benchling’s capabilities can solve these complexities